Mirum’s LIVMARLI now Authorized in Canada for Cholestatic Pruritus
Mirum Pharmaceuticals, Inc announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).